PTC-028, a specific inhibitor of BMI1, inhibits CSC self-renewal of medulloblastoma in vitro, reduces tumor burden in both local and metastatic compartments, and suppresses the tumor initiation ability of recurrent medulloblastoma in vivo [70]. This evidence concerns the gene BMI1 and medulloblastoma.